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We used a mouse nasal model of herpes simplex virus 2 (HSV-2) infection to examine the biological properties of HSV-2
wild-type (wt), TK-negative, and replication-defective strains in vivo. Nasal septa tissue is the major site of wt viral replication
post intranasal (i.n.) inoculation. The HSV-2 strain 186 syn1-1 wt virus caused lethal encephalitis at doses of 104 PFU and
above per nostril, and at lower doses no neurons in the trigeminal ganglia were positive for the latency-associated transcript,
indicating a lack of latent infection. The 186DKpn TK-negative mutant virus replicated in nasal septa tissue but showed
low-level replication in trigeminal ganglia at only one timepoint. In situ hybridization of trigeminal ganglia showed that the
number of LAT-positive neurons was proportional to the inoculum dose from 103 to 106 PFU per nare. The replication-
defective mutant virus 5BlacZ showed no replication in nasal septa tissue and no persistence of viral DNA at the inoculation
site or the trigeminal ganglia. Nevertheless, inoculation of 5BlacZ or the double-mutant dl5-29 at distal sites reduced acute
replication and latent infection of 186DKpn following intranasal challenge. This infection model provides a biological system
to test the properties of HSV-2 strains and shows that replication-defective mutant strains do not persist at sites of
inoculation or in sensory ganglia but can induce immune protection that reduces the latent viral load of a challenge virus.
© 2000 Academic Press
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1
tINTRODUCTION
The morbidity associated with human genital infection
with herpes simplex virus 2 (HSV-2) and the uncommon
but devastating complication of neonatal disease are the
impetus toward development of more effective therapies
against HSV-2. The high incidence of unrecognized clin-
ical HSV-2 disease and asymptomatic shedding post-
genital infection both suggest that the only way to sig-
nificantly impact upon transmission is through a prophy-
lactic vaccine. Recent reports of an increase in
prevalence of HSV-2 in the United States (Fleming et al.,
1997) and of a putative role for HSV-2 in facilitating the
worldwide pandemic of human immunodeficiency virus
emphasize that the development of a vaccine against
HSV-2 continues to be a high priority (reviewed by Corey
and Handsfield, 2000).
A number of vaccine strategies have been or are being
tested against HSV, including attenuated viruses, repli-
cation-impaired viruses, heterologous viral vectors ex-
pressing HSV proteins, inactivated virus, viral protein
subunits, and DNA vaccines (reviewed in Stanberry et
1 Present address: The Children’s Hospital at Westmead, Hawkes-
ury Road and Hainsworth Street, Westmead, NSW 2121, Australia.
2 To whom correspondence and reprint requests should be ad-
dressed at Harvard Medical School, Department of Microbiology and
Molecular Genetics, 200 Longwood Avenue, Boston, MA 02115-5701.
Fax: (617) 432-0223. E-mail: david_knipe@hms.harvard.edu.
137al., 2000). Many of these approaches can prevent local
disease or encephalitis. However, to reduce transmis-
sion to uninfected individuals, an effective vaccine
should not only protect against local disease in the
genital region but also reduce or prevent latent infection
of the sensory ganglia (Roizman, 1991).
The ability of HSV-2 vaccine candidates to protect
against latency has been reported in terms of reactiva-
tion of challenge virus from explanted ganglia and/or
detection of the latency-associated transcripts (LATs) in
sensory ganglia (Berman et al., 1988; Boursnell et al.,
997; Burke et al., 1991; Cremer et al., 1985; Dix and Mills,
985; Meignier et al., 1988; Schneweis et al., 1981; Spec-
or et al., 1998; Stanberry et al., 1986; Walz et al., 1977).
However, a more stringent demonstration of a reduction
in latent viral load within the sensory ganglia using more
sensitive assays for latent infection, such as quantitative
polymerase chain reaction (Q-PCR) for HSV-2 viral DNA,
was previously reported in only a few cases (Bourne et
al., 1996; Da Costa et al., 1999). Even less well described
is the ability of the vaccine candidate itself to establish
latent infection in the nervous system (Klein et al., 1984;
Meignier et al., 1988; Robertson et al., 1992; Thompson et
al., 1986) or its ability to persist at the site of inoculation
(Bourne et al., 1996).
Replication-impaired mutant viral vaccines have been
designed as replication-defective mutants (Nguyen et al.,
1992) and as single-cycle mutant viruses (Farrell et al.,
0042-6822/00 $35.00
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138 JONES, TAYLOR, AND KNIPE1994). As a test of the use of replication-defective HSV-2
strains for immunization, we previously showed that im-
munization with the HSV-2 replication-defective mutant
5BlacZ, which is defective for the gene encoding ICP8,
can elicit protection against acute and recurrent genital
disease in both the mouse and guinea pig models of
genital infection (Da Costa et al., 1997; Morrison et al.,
998) and is capable of eliciting an HSV-specific sys-
emic and mucosal immune response (Morrison et al.,
998). A double-deletion mutant of HSV-2 is also capable
f inducing protective immunity against genital challenge
Da Costa et al., 1999). In this study, we developed an
ntranasal mouse model of HSV-2 infection to examine
he HSV-2 replication-defective mutants not only in terms
f their ability to protect against latent infection but also
n terms of the in vivo behavior of the mutants at the site
f inoculation, in trigeminal ganglia (TG) and in the cen-
ral nervous system (CNS).
RESULTS
ntranasal model of HSV-2 infection
We developed a mouse model of nasal HSV-2 infection
ith which to examine the biological properties of vari-
us HSV-2 strains and to test the ability of the HSV-2
eplication-defective mutants to protect against latent
nfection by a challenge virus. We chose to use the
ntranasal route to inoculate the viruses because (1) the
ntranasal route is used frequently for immunization to
licit mucosal immunity, especially in the genital tract; (2)
he trigeminal ganglia are more accessible in mice than
re the sacral ganglia, the site of latency after intravag-
nal inoculation; and (3) the intranasal route is a major
oute for HSV-2 infection of newborns. We constructed an
ttenuated, thymidine kinase-negative mutant of the
SV-2 strain 186syn1, 186DKpn (Fig. 1A), for latency
studies because wild type HSV-2 causes lethal enceph-
alitis when inoculated into mice.
Dose curve of HSV-2 latency after intranasal inocula-
tion. To optimize conditions for establishment of latent
infection, we infected mice intranasally with doses of 101
to 106 plaque-forming units (PFU)/mouse of HSV-2
186DKpn, 101 to 105 PFU/mouse of wt virus, or an equiv-
lent volume of uninfected cell extract (CE) as a negative
ontrol. The mice were examined daily for signs of acute
nfection, neurological disease, and moribundity. Thirty
ays postinfection (p.i.), we sacrificed the surviving mice
nd removed the TG. To determine the abundance of
atently infected neurons in the TG, we performed in situ
ybridization for HSV-2 LATs using the LAT probe pBP2
Fig. 1B).
We observed that the HSV-2 TK2 strain 186DKpn was
sufficiently attenuated to use in our studies of HSV-2
latency, as none of the mice inoculated with this strain
showed signs of CNS disease or lesions at the external
nares, and all survived until sacrifice at Day 30. In con-
Wtrast, only mice infected with low doses (,104 PFU/
ouse) of wt virus survived (Table 1). The lethal dose50
(LD50) of 186DKpn after intranasal inoculation was calcu-
ated to be .106 PFU/mouse and the LD50 for wt HSV-2
was 5 3 103 PFU after intranasal inoculation.
When we examined LAT expression by in situ hybrid-
ization in the 186DKpn-infected ganglia at 28 days p.i.,
we observed a roughly linear relationship between num-
bers of LAT-positive neurons and the dose of 186DKpn
virus, between doses of 103 and 106 PFUs per mouse
Table 1). Mice that survived inoculation with wt virus did
ot show any LAT1 neurons (Table 1). We demonstrated
he specificity of the pBP2 plasmid for LAT by showing a
ack of hybridization to mock-infected tissue (Table 1)
nd by performing DNase incubation of the slides, which
id not affect the signal, and RNase digestion, which
bliterated the signal (C. A. Jones and D. M. Knipe,
npublished results). Thus, intranasal (i.n.) inoculation of
86DKpn (TK2) virus resulted in latent infection of the TG.
3
FIG. 1. Maps of viruses and plasmids used in this study. (A) Map of
the TK gene region in wt and 186DKpn viruses. A 213-bp KpnI–KpnI
deletion was made within the thymidine kinase (TK) gene (UL23) of the
wt HSV-2 (strain 186), using plasmid pEH48 to make pEH48DKpn. (B)
Origin of the LAT probe. The 3.73-kb BamHI–P fragment of HSV-2 (strain
186), which contains the LAT-encoding gene and ICP0, was cloned into
pUC19. The 876-bp BamHI–PvuI fragment was subcloned into pZERO
2.1 (InVitrogen) to obtain the pBP2 plasmid, which serves as a specific
probe for the HSV-2 LAT RNA.e are uncertain why, at doses of 10 PFU, 186DKpn
infection yielded more LAT1 neurons than did wt virus.
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139PROPERTIES OF HSV-2 MUTANT STRAINS IN MURINE MODELThis may be due to experimental variability between the
two groups of animals; alternatively, the TK2 phenotype
may increase the numbers of latently infected cells or
levels of LAT expression.
Site of replication after intranasal inoculation. To de-
termine the site of primary viral replication after i.n.
inoculation, we inoculated mice with 1 3 106 PFU/mouse
f wt 186, 186DKpn, or an equivalent volume of CE. On
ays 1, 2, and 3 p.i., animals from each group were
acrificed and the nasal septa, trachea, lung, nasophar-
nx, and stomach were removed, homogenized, and as-
ayed for infectious virus by standard plaque assay. We
bserved that the nasal septa were the major tissue
ites of replication after intranasal inoculation of both wt
nd 186DKpn viruses (Fig. 2). Some infectious wt virus
as detected from Day 1 p.i. in the trachea and lungs, as
ell. Stomach homogenates were toxic to the monolay-
rs at dilutions less than 1:100, and no infectious virus
as detected in homogenates diluted more than this.
iral titers were, on average, 10- to 100-fold greater in all
issues in wt virus-infected mice than in tissues of ani-
als inoculated with 186DKpn virus. Therefore, a signif-
cant proportion of the inoculum remains in and infects
ells in the nasal septa after intranasal inoculation, and
asal septa homogenates can be used effectively to
onitor acute viral replication after inoculation at this
ite. Infectious virus was not detected in nasal swabs
ollected at any time post i.n. inoculation (C. A. Jones and
. M. Knipe, unpublished results).
SV-2 replication-defective mutants protect against
atent infection by a challenge virus
Protection against latency by the HSV-2 replication-
efective mutant 5BlacZ. To test if immunization with
BlacZ, an HSV-2 ICP82 replication-defective mutant (Da
osta et al., 1997), would protect against latency after
T
Survival and Numbers of LAT-Positive Neurons in Trigeminal Gang
Virus
Dose
(PFU/mouse)
Percentage survival
(no. mice)
No
sco
186DKpn 106 100 (5) 1
105 100 (3)
104 100 (4)
103 100 (4)
102 100 (4)
101 100 (4)
wt 105 0
104 0
103 100 (4)
102 100 (4)
101 100 (4)
E 100 (5)ntranasal challenge with 186DKpn, mice were immu-
ized twice s.c. in the rear flank with 2 3 106 PFU/mouseFIG. 2. Viral titers in nasal septa, trachea, and lung after intranasal
inoculation. Mice were inoculated with 2 3 106 PFU of wt HSV-2 (strain
86) or 186DKpn, i.n. (N 5 3 mice/timepoint/virus strain). On Days 1, 2,
and 3 p.i., the nasal septa, trachea, lungs, and stomach were removed,
homogenized in assay media, and assayed for infectious virus by
standard plaque assay on Vero cells. Stomach homogenates were
cytotoxic to the cell monolayers at dilutions less than 1:100, at andABLE 1
lia in Mice Infected with Various Doses of HSV-2 wt or 186DKpn Viruses
. TG
red
No. sections
scored
Total No. LAT1
neurons
Mean No. LAT1
profiles/TG 6 SEM
0 540 3423 342 6 1.2
5 208 300 60 6 1.1
5 254 168 33.6 6 1.1
6 501 28 4.7 6 0.5
4 191 0
1 73 0
5 185 0
4 327 0
6 463 0above which no infectious virus was detected. Symbols: }, 186 WT; h,
186DKpn.
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140 JONES, TAYLOR, AND KNIPEof 5BlacZ or an equivalent volume of CE, at 0 and 3
weeks and given an i.n. challenge of 2 3 106 PFU/mouse
f 186DKpn or an equivalent volume of CE at 6 weeks p.i.
he TG were removed at 4 weeks postchallenge, and in
itu hybridization was performed, probing for LATs. We
bserved that immunization of mice with 5BlacZ reduced
he number of neurons expressing LATs (as detected by
n situ hybridization) by approximately ninefold after in-
ranasal challenge with the replication-competent TK2
virus 186DKpn (Table 2). The numbers of LAT-positive
neurons in the immunized animals were significantly
less than the number of positive neurons in the control
animal TG (P , 0.01; Mann–Whitney U test).
Immunization with 5BlacZ virus reduces challenge viral
burden in the TG. To test if immunization with 5BlacZ
reduced the amount of latent viral DNA in the TG, and not
just the expression of the LAT transcripts, we harvested
TG of immunized and mock-immunized mice 30 days
after i.n. challenge with 2 3 106 PFU/mouse of 186DKpn
and quantified the number of HSV-2 DNA molecules in
whole TG homogenates by quantitative PCR. Figure 3A
shows representative standards generated by PCR am-
plification of known amounts of HSV-2 DNA in ganglion
homogenates, and Fig. 3B shows PCR products from
ganglia of mock-immunized and immunized animals. We
found that mice immunized with 5BlacZ had a 43-fold
reduction in the number of viral DNA molecules in the TG
compared to that of mock-immunized mice (Table 2). This
indicated that there was a reduction in the total amount
of latent challenge virus in the TG and not just a change
in the expression of the viral gene products.
To test if the HSV-2 replication-defective mutant could
elicit protection against latent infection after intranasal
challenge by a virulent strain of HSV-2, a second exper-
iment was performed in which mice were immunized
twice s.c. with 2 3 106 PFU of 5BlacZ or an equivalent
olume of cell lysate, and again challenged with 2 3 106
PFU/mouse of 186DKpn. In addition, a group of 5BlacZ-
mmunized mice was challenged with 2 3 106 PFU/
ouse of wt HSV-2 virus. The mock-immunized animals
T
Effect of Prior Immunization with 5BlacZ on Numbers of Neuro
Immunogen Challenge
Number of ganglia
analyzed by ISHa
M
neu
CEd 186DKpn 6
5BlacZ 186DKpn 6
CEd CEd 3
a All available sections were analyzed by in situ hybridization for LA
b Contralateral ganglia were analyzed by quantitative PCR for HSV D
c Values represent log10 geometric means 6 SEM. Level of detectio
d CE 5 uninfected cell extract.ere not challenged with the wt strain because we had
hown in earlier experiments (Table 1) that wt HSV-2auses lethal encephalitis in mice, so there were no
urvivors with latent infection. In this experiment we
ound a 1000-fold reduction in the number of viral DNA
olecules in mice immunized with 5BlacZ and chal-
enged with 186DKpn, compared to that of mock-immu-
ized mice (Table 3). The level of viral DNA in TG from
mmunized mice was significantly less than the level of
NA in TG from mock-immunized mice (P , 0.01;
ann–Whitney U test). Mice that had been immunized
rior to challenge with the virulent wt strain did not
evelop clinical signs of HSV-2 CNS disease and had
00-fold fewer DNA molecules than mock-immunized
FIG. 3. Effect of immunization with 5BlacZ on the latent viral load of
challenge virus. Mice were immunized twice s.c. with either 5BlacZ or
CE and challenged i.n. with 186DKpn at 3 weeks postboost. The latent
viral load was determined by PCR detection of HSV-2 DNA. (A) An
autoradiograph of a probed Southern blot of PCR products of HSV-2
DNA standards in TG homogenates. Numbers above the blot represent
the number of HSV-2 DNA molecules in each reaction. (B) An autora-
diograph of a probed Southern blot of PCR products of TG homoge-
nates from mice immunized with 5BlacZ (5BlacZ/186DKpn; six samples
from six mice) or from mice mock-immunized with CE (CE/186DKpn;
five samples from five mice). CE/CE lanes (three samples from three
mice) show products from mice mock-immunized and mock-chal-
ntly Infected with Challenge Virus and Latent Viral DNA Load
. LAT1
nglionb
Number of ganglia
analyzed by PCR
Log10 mean no. HSV DNA
molecules/ganglionc
22.4 5 4.02 6 0.21
2.4 6 2.39 6 0.39
3 ,1
10 molecules/TG.ABLE 2
ns Late
ean no
rons/ga
75.8 6
8.3 6
0
T.
NA.lenged with cell extract. Each lane contains PCR products of one-half
of a TG homogenate of a single mouse. M, markers.
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141PROPERTIES OF HSV-2 MUTANT STRAINS IN MURINE MODELmice challenged with 186DKpn (Table 3). The levels of
DNA were again significantly different (P , 0.01; Mann–
Whitney U test). Therefore, immunization with 5BlacZ
rotected against latent infection by attenuated or viru-
ent challenge viruses.
An important safety concern of live-attenuated HSV
accines is whether they could recombine with a wild-
ype (wt) virus in vivo to form a virulent strain. For this
eason, an HSV-2 replication-defective double-deletion
utant, dl5-29 (defective in two essential genes for
SV-2 replication: UL5 and UL29), has been constructed
Da Costa et al., 1999). The preceding experiment was
erformed together with a subset of mice that had been
mmunized with dl5-29, the double-deletion mutant, and
hallenged intranasally with 186DKpn or wt HSV-2. Im-
unization with dl5-29 reduced latent infection by chal-
enge virus DNA by several thousand-fold (Da Costa et
l., 1999). Thus dl5-29, the double-deletion mutant, re-
uced the latent viral DNA burden in mouse TG at least
s well as the single mutant 5BlacZ, against wt or
86DKpn intranasal challenge.
SV-2 replication-defective mutants protect against
hallenge virus infection by reducing viral replication
t the site of inoculation and in the trigeminal ganglia
To determine the stage of infection at which the vac-
ine-induced immune response acted to reduce latent
nfection by the challenge virus, a subgroup of mice in
he preceding experiment were euthanized on Days 1 to
postchallenge, and their nasal septa, TG, and brains
ere removed. Infectious virus in homogenates of these
issues was titrated. We observed that mice immunized
ith either the double mutant dl5-29 or the single mutant
BlacZ had a 10- to 100-fold reduction in replication in
he nasal septa, as early as Day 1 postchallenge with
t186 virus, and a faster rate of clearance of productive
nfection at this site (Fig. 4A). A 100-fold reduction in viral
iter was also detected when immunized mice were chal-
TABLE 3
Effect of Prior Immunization with 5BlacZ on Latent DNA Load
of Challenge Virus
Immunogen Challenge No. TG
DNA
molecules/gangliona
5BlacZ 186DKpn 6 1.1 3 101 6 2.0 3 100
5BlacZ wt 6 1.4 3 102 6 3.9 3 101
CEb 186DKpn 6 8.8 3 104 6 4.9 3 104
a Lower limit of detection was 10 molecules/TG and values represent
eometric means 1 SEM.
b Cell extract. The data from this group of mice were previously
reported (Da Costa et al., 1999). They are included here as control
animals for this experiment, which was performed concurrently.enged with the 186DKpn strain (C. A. Jones and D. M.
nipe, unpublished results) (Fig. 4A). Therefore, the im-mune response induced by the double mutant dl5-29
acted to reduce latent infection by reducing replication at
the site of inoculation of the challenge virus. Although
the immunity induced by dl5-29 appeared to clear chal-
lenge virus from the nasal tissue faster than the immunity
induced by 5BlacZ (Fig. 4A), we have not observed dif-
ferences between immunity induced by single and dou-
ble mutants in other experiments (Da Costa et al., 1999).
In trigeminal ganglia, thymidine kinase-deficient
trains are characteristically replication-defective; thus,
nly the TG of mice challenged with the wt strain were
ssayed for infectious virus at this site. We observed that
mmunized mice had low levels of infectious virus in the
G on Day 2 postchallenge, which represented a 2.5
og10 reduction in titer compared to that of mock-immu-
nized mice. Infectious virus in the TG of immunized mice
was cleared by 4 days postchallenge (Fig. 4B). Therefore,
the HSV-2 replication-defective mutants protected
against latent infection by reducing replication of the
challenge virus both at the site of inoculation and in the
TG.
In brain tissue we detected infectious wt virus only in
mock-immunized mice, observed first on Day 3 postchal-
lenge and peaking on Day 5, after which time the mice
died. No infectious wt virus was detected in the brains of
mice immunized with either the single or double HSV-2
replication-defective mutant (Fig. 5), indicating that im-
munization also protected against virus reaching the
CNS.
Do the replication-defective mutants establish latency
in the TG after intranasal inoculation?
The ability of a potential vaccine strain to establish
latent infection is important to determine as a safety
feature and as a control for the immunization experi-
ments. To determine if 5BlacZ could establish latent
infection in the TG as detected by in situ hybridization for
LATs, a group of mice was mock-immunized with CE at 0
and 3 weeks and challenged with 5BlacZ intranasally 6
weeks later. TG were harvested 30 days p.i. One trigem-
inal ganglion per mouse was sectioned and probed for
LATs at 4 weeks postchallenge. We observed that 5BlacZ
TABLE 4
Primers and Probes
Gene Oligonucleotide Sequence (59 to 39)
K 2TK-1 TGG ATT ACG ATC AGT CGC C
2TK-2 ACA CCA CAC GAC AAC AAT GC
2TK-3 CCA TCG CCG AGA TAC GCG AC
ouse
adipsina MT-1 AGT GTG CGG GGA TGC AGT
MT-2 ACG CGA GAG CCC CAC GTAa Sequences were reported by Katz et al. (1990).
a
D
s
f
1
1 ols: },
5 nged w
142 JONES, TAYLOR, AND KNIPEdid not establish latent infection in the TG, as determined
by in situ hybridization for LAT expression (Table 3).
To test if 5BlacZ DNA could be detected in the TG, we
ssayed the other ganglion of these same mice for viral
NA by Q-PCR 30 days post i.n. inoculation. We ob-
FIG. 4. Effect of immunization on challenge virus replication in nasal
to 5 p.i. in the nasal septa (A) or on Days 1–5 p.i. in the TG (B) of mi
challenged i.n. 4 weeks postboost with wt (strain 186 virus). Values sho
the input titer as confirmed by titration of the inoculum postinocula
/timepoint/group for 4 h p.i. For the TG, N 5 8/timepoint/group. Symb
BlacZ, challenged with 186 wt virus; T , immunized with dl5-29, challeerved that 5BlacZ DNA could be detected in only one of
ive TG tested (of five different mice) to the order of 1 toa few molecules (Fig. 6). No DNA was detected in mice
given CE i.n. (Fig. 6) or in the water blanks (C. A. Jones
and D. M. Knipe, unpublished results). Therefore, 5BlacZ,
the single mutant rarely and inefficiently establishes la-
tency in the TG.
and trigeminal ganglia. Acute replication was assayed at 4 h and Days
unized twice s.c. with dl5-29, 5BlacZ, or CE (mock immunization) and
geometric mean titers 6 SEM, except for time zero, which represents
or the nasal septa N 5 4/timepoint/group for Days 1–5, and N 5
immunized with CE, challenged with 186 wt virus; E, immunized with
ith 186 wt virus.tissue
ce imm
wn are
tion. FTo test whether infectious dl5-29 reaches the TG, we
inoculated mice i.n. with 1 3 106 PFU per naris of dl5-29,
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143PROPERTIES OF HSV-2 MUTANT STRAINS IN MURINE MODEL186DKpn, or wt virus, and harvested the TG at 4 h, 20 h,
and on Days 1 to 5 and 7 p.i. The titer of infectious virus
in the TG was determined on a complementing cell line
(Fig. 7). No infectious dl5-29 virus was detected at any
timepoint in the TG, whereas wt virus could be detected
by Day 3 p.i., peaking on Day 4 p.i. Low levels of infec-
tious 186DKpn could be detected only on Day 6 p.i.
Assays of dl5-29 DNA in the TG showed that it accumu-
lated there in low levels only transiently at Days 2 and
3 p.i. (Da Costa et al., 1999).
Lack of persistence of replication-defective mutant
DNA at the site of inoculation
We previously showed that the HSV-1 replication-de-
fective mutants elicit durable immune protection in the
mouse eye model of disease (Morrison and Knipe, 1994).
The mechanism of this long-lived immunity is unclear.
One possible explanation is the presence of a persistent
antigenic stimulus. Intranasal immunization with 5BlacZ
induced protective immunity in mice (Morrison et al.,
1997). To test if the HSV-2 double-mutant dl5-29 DNA
persists at the site of inoculation, mice were given i.n.
2 3 106 PFU/mouse of dl5-29, 186DKpn, wt virus, or an
equivalent volume of CE. Animals were sacrificed on
Days 1 to 7 p.i., and the nasal septa were removed. The
3
FIG. 5. Effect of immunization on challenge virus replication in the c
1, 3, and 5 postchallenge of mice immunized twice s.c. with 5BlacZ, dl5-2
was performed on a cell line (V5-29) that complements the defective ge
}, mock-immunized with cell extract, challenged with 186 wt virus; , im
hallenged with 186 wt virus.tissues were homogenized and 4 of each sample was
assayed for infectious virus (on a complementing cell
a
pline) while 18 was used to determine the abundance of
iral DNA by Q-PCR. We reported elsewhere that the titer
f infectious dl5-29 declined rapidly to undetectable lev-
ls by Day 1 p.i. (Da Costa et al., 1999). The presence of
l5-29 DNA in the nasal septa was detected until Day
p.i. WT and 186DKpn DNAs were detected through at
east Days 5 and 7, respectively (Fig. 8). Therefore, dl5-29
NA either did not persist at the site of inoculation in
asal septa tissues or persisted at levels too low to be
etected.
DISCUSSION
We used a mouse nasal model of HSV-2 infection to
xamine the in vivo behavior of several HSV-2 strains
nd to examine the ability of HSV-2 replication-defective
utants to protect against latent infection by challenge
irus. Infection of HSV-2 by the intranasal route is of
ignificance because this is a frequent route of virus
ntry in the newborn and because it may be used as a
oute of immunization to induce mucosal immunity, par-
icularly in the genital tract. Prior to this work, intranasal
SV-2 infection had not been characterized in adult
ice. The inoculation of HSV-1 into the nares of animals
as previously studied extensively as a model of HSV-
nduced encephalitis (Beers et al., 1993; Drummond et
ervous system. Titer of infectious virus in the brain is shown on Days
E and challenged i.n. with wt (strain 186) 4 weeks postboost. The assay
dl5-29. Individual values are shown. N 5 4/timepoint/group. Symbols:
d with 5BlacZ, challenged with 186 wt virus; T , immunized with dl5-29,entral n
9, or C
nes inl., 1994; Esiris et al., 1995; Walev et al., 1995) and
neumonia (Adler et al., 1997; Davis et al., 1997). In
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144 JONES, TAYLOR, AND KNIPEcontrast, reports of intranasal inoculation of HSV-2 had
been limited to a rabbit model of keratitis (Stroop et al.,
994), neonatal models of mice (Kern et al., 1986) and
uinea pigs (Bravo et al., 1994; Mani et al., 1996), or in
tudies of passive immunotherapy in mice (Erlich and
ills, 1986). In these reports, the initial events after
noculation of virus into the nares were not extensively
escribed. Therefore, we chose to describe the events
fter intranasal inoculation of HSV-2 and to evaluate
asal septa homogenates as a tool for monitoring repli-
ation at this site.
We demonstrated that after intranasal inoculation of
SV-2 in a small volume, the majority of the inoculum
emains in the nasal passage, with only small amounts
eing swallowed or aspirated, because the major site of
eplication is in the nasal tissue. This has important
mplications for use of this route as a vaccine. In addi-
ion, nasal septa homogenates proved a valuable tool for
FIG. 6. Lack of persistence of 5BlacZ DNA in trigeminal ganglia. The
in mice inoculated i.n. with 5BlacZ (five TG samples from five mice) or C
1/ 2’s) of a probed Southern blot of Q-PCR products of one-half of TG h
FIG. 7. Acute viral replication in trigeminal ganglia. Infectious virus wa
ith dl5-29, 186DKpn, or wt virus (N 5 8/timepoint/group). Values shown are
n a cell line (V5-29) that complements the defective genes in dl5-29. Symboonitoring replication at the site of inoculation, given the
bsence of infectious virus in nasal swabs in mice. The
ack of infectious virus in nasal swabs was likely due to
he small diameter of murine nasal passages. This con-
rasts with the results with rabbits (Stroop et al., 1994) or
uinea pigs (Bravo et al., 1994; Mani et al., 1996), in
hich nasal swabs readily detect infectious virus.
HSV-2 strains have an enhanced capacity to enter and
eplicate in the central nervous system of mice (Richards
t al., 1981) and newborn guinea pigs (Mani et al., 1996)
hen compared to that of HSV-1. Thus, we isolated and
tilized a thymidine kinase-negative mutant virus to
tudy latent infection following intranasal inoculation.
SV-2 strains deficient for the expression of the thymi-
ine-kinase gene were previously reported to be neu-
oattenuated when given via the vaginal route in mice
McDermott et al., 1984) and guinea pigs (Stanberry et al.,
985), and via the corneal route in rabbits (Stroop et al.,
of HSV-2 viral DNAs in TG were determined at 30 days postchallenge
from 3 mice). Shown is an autoradiograph with a long exposure (.2
nates run in duplicate. M, markers.
d in TG of mice at 4 h, 20 h, and on Days 1–5 and 7 post i.n. inoculationlevelss titrate
the geometric means of the viral titers 6 SEM. Assay was performed
ls: }, 186 wt virus; h, 186DKpn TK2 virus; 3, dl5-29 virus.
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145PROPERTIES OF HSV-2 MUTANT STRAINS IN MURINE MODEL1994). Others reported HSV-2 TK2 strains with single
missense mutations in the nucleotide-binding site that
retained neurovirulence in mice (Tanaka et al., 1993). In
hese experiments we demonstrated that an HSV-2 TK2
construct in the background of a virulent HSV-2 strain
(186) was neuroattenuated, despite being administered
in close proximity to the CNS. This is consistent with the
findings of Nishiyama et al. (1991), who inoculated mice
with a TK2 strain in the same background as that of our
study virus (although the location and size of the muta-
tion were different) via the intracerebral route and
showed an LD50 . 10
5 PFU/mouse. After intranasal in-
oculation, this TK2 strain, like the wt strain, grew pre-
dominantly in the nares, but did so 10- to 100-fold less
efficiently than wt. We also observed some low-level
replication in the TG, which was not reported for other
HSV-2 TK2 mutants in the TG, but seen with the same
mutation in another genetic background (strain 333) in
the sacral ganglia (McDermott et al., 1984). It is possible
that within the HSV-2 background, the block to acute
infection in the TG is more easily overcome by comple-
mentation with cellular factors.
Latent infection of trigeminal ganglia by HSV-2 was
previously described by Mitchell et al. (1990) using an
ttenuated strain (HG52) given via the corneal route. Our
tudies showed that the number of LAT-positive neurons
as proportional to the dose of virus inoculated intrana-
FIG. 8. Lack of persistence of dl5-29 viral DNA in nasal tissue. The
post i.n. inoculation with dl5-29, 186DKpn, or wt (strain 186) was deter
86DKpn TK2 virus; T , dl5-29 virus.ally, thus providing a quantitative assay for the number
f cells that are latently infected.
a
trotection against latent infection as measured by
wo assays
Having shown that the number of LAT-positive cells
as proportional to the virus inoculum dose, we exam-
ned the effect of prior immunization with a replication-
efective mutant virus, 5BlacZ, on the number of cells
hat become latently infected with an HSV-2 challenge
train following intranasal inoculation. Prior immuniza-
ion reduced the number of LAT-positive cells by approx-
mately ninefold. In contrast, PCR measurement of viral
NA in the latently infected ganglia showed a 43-fold
eduction in viral DNA in the latently infected ganglia as
result of prior immunization. This suggests that there is
reduction in the number of latently infected cells and a
eduction in the number of viral DNA molecules in the
eurons that do become latently infected as a result of
reexisting immunity.
It remains to be determined whether the number of
atently infected cells or the DNA content per cell—or
oth factors—is the more relevant determinant in defin-
ng the likelihood of reactivation and recurrent disease.
everal studies have shown a relationship between the
evel of latent infection and the probability of reactivation,
ut these studies did not distinguish between DNA con-
ent and number of latently infected cells as being the
mportant factor in defining reactivation ability. Perng et
urse of viral DNA accumulation in nasal septa tissue at various times
by quantitative PCR for HSV-2 viral DNA. Symbols: }, 186 wt virus; h,time col. (1996) used a rabbit ocular infection model to show
hat an ICP34.5-deletion mutant showed wild type levels
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146 JONES, TAYLOR, AND KNIPEof spontaneous reactivation at high doses. Both Mag-
gioncalda et al. (1996) and Gordon et al. (1996) correlated
decreased rates of reactivation as determined by explant
cocultivation with a reduced number of latently infected
rabbit TG after corneal inoculation of LAT2 mutants.
ekstrom-Hines et al. (1998) correlated the recurrence
ate of disease of HSV-1 and HSV-2 strains from the
acral ganglia of guinea pigs to the level of DNA in the
anglia at this site and not to the strain or concentration
f LATs. The importance of a reduction of latent viral
urden in humans was previously shown indirectly by
linical studies that correlate the frequency of recurrence
f genital herpes with the severity of the initial lesion
nd, hence, the burden of latent DNA in humans (Corey
t al., 1983). Whether there exists in humans, as Gordon
t al. (1995) hypothesized to exist in rabbits, a threshold
evel of latency required for efficient reactivation has not
et been established.
Prior immunization reduced challenge virus replication
n both nasal tissue and in the trigeminal ganglia. Im-
une effector mechanisms may function at both primary
nd secondary sites of viral replication or just at the
rimary site of infection. The extent to which primary-site
eplication versus secondary-site replication is affected
ay vary with different experimental systems because,
n another system, we observed that reduced viral rep-
ication in the ganglia may be the major effect of preex-
sting immunity (M. Kramer and D. M. Knipe, manuscript
n preparation).
The immune mechanism(s) responsible for reducing
cute viral replication and latent infection also remains
o be defined. Clearance of virus from infected tissue
as previously shown to be predominantly CD41 T-cell-
dependent in mice after intravaginal inoculation of HSV-2
(Lekstrom-Hines et al., 1998). In contrast, passage of
virus from the TG to the CNS was previously shown to be
reduced by the presence of HSV-specific antibody
(Kapoor et al., 1982; Simmons and Nash, 1985).
Lack of persistence of the replication-defective
mutants in the CNS and in the periphery
HSV-2 vaccine candidates have only rarely been as-
sessed for their ability to establish latent infection in their
own right (Klein et al., 1984; Meignier et al., 1988; Thomp-
son et al., 1986). Lack of ability to establish latent infec-
tion would be an important characteristic, from a safety
standpoint, to reduce the possibility of recombination
with a wild type strain in vivo. We showed that the single
mutant 5BlacZ rarely and inefficiently established latent
infection, as detected by quantitative PCR for viral DNA
and in situ hybridization for LAT. We used this same
system to show that the double-deletion mutant dl5-29
shows low, transient accumulation of viral DNA in the
trigeminal ganglia but does not persist in that tissue (Da
Costa et al., 1999). These results show that these mu- ttants establish latent infection to a greatly reduced de-
gree or that they do not establish a stable latent infec-
tion. Further studies on the time course and nature of the
mutant viral DNA in the ganglia are underway in our
laboratory.
HSV-1 replication-defective mutants were previously
shown to elicit a durable immune response (Morrison and
Knipe, 1994). Durable antibody responses could be due to
long-lived plasma cells and thus independent of antigenic
stimulus and T-cell activation. Protective immunity, which is
highly dependent on CD41 T cells, is also durable (Morri-
son and Knipe, 1996). This could be due to a memory T-cell
response or to persistence of an antigenic stimulus. HSV
DNA was previously reported to be present at a number of
sites outside the CNS (reviewed in Hill, 1985). For HSV-2,
this has largely been within the footpad of mice (Clements
and Subak-Sharpe, 1988) and within the vagina of guinea
pigs (Scriba, 1981), although the frequent recurrences seen
in guinea pigs has made the phenomenon of peripheral
persistence contentious in that system. Simmons et al.
(1997) recently showed the presence of HSV-1 viral DNA in
keratinocytes of mouse footpads after scarification. This
DNA was detected for more than 2 weeks after the disap-
pearance of infectious virus and viral antigens, and the
location of the DNA became more superficial with time. We
previously showed that an HSV-1 replication-defective mu-
tant virus persists in an infectious form up to 7 days post-
inoculation in the footpad (Morrison and Knipe, 1994). In-
fectious HSV-2, however, is rapidly cleared from the nasal
septa after intranasal inoculation of the HSV-2 replication-
defective mutant (Da Costa et al., 1999). We demonstrated
in these experiments that the viral DNA of the HSV-2 repli-
cation-defective mutants does not persist beyond 5 days
p.i. in the nares after intranasal inoculation. In addition, we
were also unable to demonstrate persistence of dl5-29 (the
HSV-2 double-replication-defective mutant) DNA in the skin
after intradermal inoculation at Days 3 and 30 p.i. and in
muscle at Day 30 p.i. after intramuscular injection (C. A.
Jones and D. M. Knipe, unpublished results). Nor did we
demonstrate dl5-29 DNA in the regional lymph nodes at
Day 30 after intradermal inoculation into the face (C. A.
Jones, M. F., Kramer, and D. M. Knipe, unpublished results).
This suggests that the durable immune protection elicited
by these replication-defective strains is due to a memory
immune response that can be rapidly mobilized to provide
protective immunity. The lack of persistence of these repli-
cation-defective mutant strains combined with their ability
to induce long-lived immune responses provide some
unique features for their use as vaccines and vaccine
vectors.
MATERIALS AND METHODS
Viruses and cells
1The origin of the 186 syn -1 strain of HSV-2 used as
he wild-type (wt) strain in these experiments was de-
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147PROPERTIES OF HSV-2 MUTANT STRAINS IN MURINE MODELscribed previously (Spang et al., 1983). The construction
of 5BlacZ, the replication-defective mutant of HSV-2
strain 186 syn1-1 defective for the gene encoding ICP8
UL29) due to insertion of lacZ coding sequences, was
escribed previously (Da Costa et al., 1997), and the
construction of dl5-29, a replication-defective mutant of
HSV-2 strain 186syn1 defective in UL29 and UL5, is
reported elsewhere (Da Costa et al., 1999, 2000).
HSV-2 strains 186 and 186DKpn were propagated and
assayed on Vero cells as described previously (Gao and
Knipe, 1989), and 5BlacZ and dl5-29 were propagated on
V5-29 cells that were stably transfected with UL5 and
UL29 (Da Costa et al., 1997, 1999, 2000). For immuniza-
tion experiments, all stocks, including wild-type strains,
were titered on the complementing cell line.
Construction of 186DKpn. A thymidine kinase-negative
mutant of HSV-2 strain 186 syn1-1 was constructed by an
pproach similar to that of McDermott et al. (1984), by
eleting a 213-bp KpnI–KpnI fragment from the plasmid
EH48 (Spang et al., 1983), which contains the HindIII–
coRI fragment of HSV-2 strain 186 from approximately
.28–0.31 map units inserted into pBR322. The resulting
lasmid, pEH48DKpn, was cotransfected with HSV-2 wt
train 186 DNA (Fig. 1), as described elsewhere (Da
osta et al., 1997). The mutant virus was selected using
00 mM acyclovir and, after three rounds of plaque pu-
rification, the presence of the mutation was confirmed by
Southern hybridization (Da Costa et al., 1997). Digestion
of the mutant DNA with PvuII demonstrated a lack of the
1.5-kbp fragment from the TK gene and a new, faster-
migrating fragment (results not shown). This mutant virus
was named 186DKpn.
Construction of the HSV-2 LAT probe plasmid pBP2.
The HSV-2 LAT probe plasmid pBP2 was constructed by
digesting HSV-2 strain 186 syn1-1 DNA with BamHI (New
ngland Biolabs, Beverly, MA) and cloning fragments in
he range of 3–5 kbb which would contain the BamHI–P
ragment (shown to be 3.4 kbp in strain 333 by Mitchell et
l., 1990) into pUC19. The presence of the desired insert
as confirmed by restriction endonuclease analysis. To
nsure that the probe did not contain DNA that hybrid-
zed to ICP0 gene transcripts, the 876-bp BamHI–PvuI
ragment within the BamHI–P fragment was subcloned
nto pZERO 2.1 (InVitrogen, San Diego, CA), to give the
lasmid pBP2 (Fig. 1B). The presence of the correct
nsert was again confirmed by restriction digest patterns
nd by comparing the DNA sequence of the insert to a
ublished sequence of the LAT-encoding region in HSV-2
train HG52 (Davison et al., 1981).
nimal protocols
Six-week-old female Balb/c mice (Taconic Farms, Ger-
antown, NY) were acclimated for 1 week prior to use.
ll experiments were conducted in accordance with the
nstitutional guidelines for animal welfare.Intranasal inoculation of virus. Mice were anesthetized
ith metophane, and 5 ml of virus stock was delivered
into each nostril with the aid of a micropipettor. The
inoculum was subsequently inhaled by the mouse. The
dose of virus administered was 1 3 106 PFU/naris, un-
less stated otherwise. For immunization studies, unin-
fected cell extract from the same cell line on which the
immunogen was derived was administered in the same
volume.
Subcutaneous immunization. The fur was clipped at
the base of the tail to expose the skin, and a dose of virus
equal to 1 3 106 PFU or an equivalent volume of unin-
ected cell extract (CE) in a total volume of 20 ml of saline
was injected subcutaneously (s.c.) into the left rear flank
near the base of the tail with a 26-gauge needle.
Harvesting of tissue samples. All mice were eutha-
nized prior to harvesting of tissue samples. Trigeminal
ganglia, brains, nasal septa, and internal organs for stan-
dard plaque assay were removed by sterile technique
and placed into 1.0 ml of assay media. Nasal septa were
harvested by stripping skin and subcutaneous tissue
from the face of the mouse, dissecting through each
external nasal orifice to the ipsilateral orbit and then
extending the incision on both sides from the orbit to the
frontal lobe to form a diamond-shaped plate of bone. The
bone flap was carefully removed, and the rudder-shaped
nasal septa were identified in the midline. The nasal
septa, complete with epithelial lining, were removed us-
ing sterile technique after dissecting the tissue from its
anterior attachment.
Assays of acute infection
Tissue samples that were used solely for assay of
infectious virus were placed in sterile vials containing 1.0
ml of assay media and then frozen at 280°C until use. At
the time of assay, the tissue was thawed on ice and
homogenized using a sterile Kontes pestle (Garber et al.,
1997). Standard plaque assay was performed on the
appropriate cells as described elsewhere (Knipe and
Spang, 1982).
In situ hybridization
Trigeminal ganglion samples for in situ hybridization
were placed into sterile vials and frozen at 280°C in
OCT compound embedding medium until they were
cryosectioned. No evidence of tissue desiccation was
present when the samples were sectioned. The TG were
sectioned at 8-mm thickness and placed serially on a
lide to allow correction for double counting of LAT-
ositive profiles within the one neuron. TG sections were
robed using the double-stranded DNA LAT probe pBP2,
abeled with [a-35S]dATP and -dCTP (Amersham, Arling-
ton Heights, IL) by nick translation (Boehringer-Mann-
heim, Indianapolis, IN). Occasional lost sections were
recorded and corrected for in the final count, although all
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148 JONES, TAYLOR, AND KNIPEremaining sections were examined and counted. The
method used for in situ hybridization was described
previously (Garber et al., 1997; Kosz-Vnenchak et al.,
1993).
Preparation of ganglionic DNA and PCR methods
Trigeminal ganglia were collected under stringent con-
ditions to avoid contamination and were stored at 280°C
until digestion. Tissues were handled and assays were
performed as outlined by Kramer and Coen (1995), with a
few modifications. Specimens were digested with pro-
teinase K (0.2 mg/ml) in a volume of 50 ml. Digestion was
t 50°C for 12–18 h. The enzyme was inactivated by
eating the mixture to 95°C for 10 min. One-half (25 ml) of
he digested TG sample was assayed directly for viral
NA using the Advantage-GC Genomic Polymerase Mix
Clontech, Palo Alto, CA) as per the manufacturer’s in-
tructions together with Perfect Match Polymerase En-
ancer (Stratagene, La Jolla, CA) in a final volume of 100
ml. Primers and the probe for the HSV-2 gene are listed
in Table 4. PCR mixtures were denatured at 94°C for 7
min, cycled at 94°C for 1 min, 55°C for 1 min, and 72°C
for 1 min for 30 cycles. Each set of samples was assayed
with a series of HSV-2 DNA standards composed of TG
DNA and known amounts of HSV-2 186 DNA, prepared
as described elsewhere (Katz et al., 1990), in parallel with
appropriate mock-infected tissue and water blanks. PCR
products were then resolved on an 8% polyacrylamide
gel, stained with SYBR-Green 1 (Molecular Probes, Eu-
gene, OR), and visualized with UV light. Visible DNA
products were analyzed using the Fluor-S MultiImager
(Bio-Rad, Richmond, CA) system. As the majority of prod-
ucts were of low abundance, the DNA was transferred to
Genescreen Plus (NEN Research Products, Boston, MA),
prehybridized, probed, and washed as previously de-
scribed (Kramer and Coen, 1995). The internal oligonu-
cleotide 2TK-3 (Table 4) was end-labeled with [a-32P]ATP
ICN, Irvine, CA) to a specific activity greater than 1 3 108
cpm/mg. The labeled filter was then exposed to a Mo-
ecular Imager cassette (Bio-Rad) for 5 to 24 h. The
mount of DNA was quantified after either analysis using
he MultiAnalyst/Macintosh software (Bio-Rad). When
he entire TG was not directly digested and analyzed, the
ecovery was normalized for the amount of cellular DNA
y coamplification for the single-copy mouse adipsin
ene as described elsewhere (Kramer and Coen, 1995).
rimers for the mouse adipsin gene (Table 4) were as
eported by Katz et al. (1990).
Statistics
For the immunization studies, the Mann–Whitney U
test was used to determine the significance of the dif-
ferences in (1) the numbers of LAT-positive neurons by
ISH or (2) the abundance of HSV-2 viral DNA in the TG byQ-PCR in latently infected trigeminal ganglia of mice
immunized with 5BlacZ or mock-immunized with CE.
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